Structural and cellular insights into DCTPP1 antagonists and their synergistic action with DNMT inhibitors
Структурные и клеточные данные об антагонистах DCTPP1 и их синергическом действии с ингибиторами ДНМТ
2026-06-15
SCID: 54.1/27eywyq2
Discuss with AI
DCTPP1DCTPP1 inhibitorsX-ray crystallographydecitabine synergynucleotide pyrophosphatase
Figures from the paper
Abstract (AI)
DCTPP1 is a nucleotide pyrophosphatase that helps preserve genomic stability and epigenetic programming by hydrolyzing and preventing the misincorporation of methylated base-modified deoxycytosine triphosphates into DNA. Through this role, DCTPP1 can degrade the efficacy of nucleotide analog-based DNA methyltransferase inhibitors and thus represents a compelling therapeutic target in cancer treatment. To identify prospective antagonists of DCTPP1, we conducted a high-throughput chemical screen against the enzyme, identifying both existing and previously unreported inhibitor classes with potent submicromolar activity. Structural characterization using X-ray crystallography revealed that the inhibitors all occupy DCTPP1's nucleotide-binding pocket, associating primarily with a pair of tryptophans and two critical histidine residues that mimic interactions observed with natural substrates. Biochemical assays using modified chemical scaffolds confirmed the relevancy of the observed DCTPP1-antagonist interactions, while cell-based experiments demonstrated significant synergy between the lead inhibitors and the nucleoside analog decitabine in blocking the growth of prostate cancer cells. The specificity and efficacy of the compounds were further validated through loss- and gain-of-function studies, confirming the dependence of their therapeutic synergy on DCTPP1 activity. These findings advance our understanding of DCTPP1 as a therapeutic target while uncovering chemical scaffolds that can potentiate the action of existing nucleotide-based cancer therapies.
Key Findings
1
Biochemical assays with modified scaffolds confirmed the importance of the observed DCTPP1–antagonist interactions for inhibitory activity.
2
High-throughput chemical screening identified existing and novel inhibitor classes of DCTPP1 with potent submicromolar activity.
3
Lead DCTPP1 inhibitors synergize with the nucleoside analog decitabine to significantly block prostate cancer cell growth in cell-based experiments.
4
Loss- and gain-of-function studies validate that the therapeutic synergy between inhibitors and decitabine depends on DCTPP1 activity.
5
X-ray crystallography shows inhibitors bind in DCTPP1's nucleotide-binding pocket, interacting mainly with two tryptophans and two critical histidine residues.
Research Object
DCTPP1 enzyme (nucleotide pyrophosphatase) and its small-molecule antagonists
Research Subject
Molecular binding interactions and inhibitory effects of identified antagonists on DCTPP1 (structural occupation of the nucleotide-binding pocket and key residues) and the resulting synergistic anti-proliferative efficacy with DNMT inhibitors (e.g., decitabine) in cancer cells
Publication Details
Publication Date
2026-06-15
Journal
Publisher
ISSN
Cited by
0
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest